The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

Transplantation

Volumn 102, Issue 6, 2018, Pages 900-931

  Kotton, Camille N ^a   Kumar, Deepali ^b   Caliendo, Angela M ^c   Huprikar, Shirish ^d   Chou, Sunwen ^e   Danziger Isakov, Lara ^f   Humar, Atul ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c RHODE ISLAND HOSPITAL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CHEMOKINE RECEPTOR CCR6; CIDOFOVIR; CYTOMEGALOVIRUS VACCINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GANCICLOVIR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 2; VALACICLOVIR; VALGANCICLOVIR; VIRUS ANTIGEN; ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD TRANSFUSION; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; CRITICAL ILLNESS; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; GRAFT SURVIVAL; HUMAN; INFECTION PREVENTION; INFECTION RISK; INNATE IMMUNITY; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT MONITORING; PEDIATRICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT INFECTION; SEROCONVERSION; SYMPTOMATOLOGY; TREATMENT DURATION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REACTIVATION; CONSENSUS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; OPPORTUNISTIC INFECTION; RISK FACTOR; STANDARDS; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CONSENSUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; RISK FACTORS; TREATMENT OUTCOME;

EID: 85046370425     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000002191     Document Type: Article

References (388)

1. Griffiths PD, Emery VC. Taming the transplantation troll by targeting terminase. N Engl JMed. 2014;370:1844-1846.
2. Stern M, Hirsch H, Cusini A, et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation. 2014;98:1013-1018.
3. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant. 2013;13(Suppl 3):24-40. quiz 40.
4. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89:779-795.
5. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333-360.
6. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336:1049-1051.
7. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926.
8. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744.
9. Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources use into grading recommendations. BMJ. 2008;336:1170-1173.
10. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106-1110.
11. de Man RA, M Balk AH, Jonkman FA, et al. Patient to patient hepatitis B transmission during heart biopsy procedures. A report of the European Working Party on Viral Hepatitis in Heart Transplant Recipients. J Hosp Infect. 1996;34:71-72.
12. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336:995-998.
13. Kish MA. Infectious Diseases Society of America. Guide to development of practice guidelines. Clin Infect Dis. 2001;32:851-854.
14. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6:262-274.
15. Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87-91.
16. DelforgeML, Desomberg L, Montesinos I. Evaluation of the new LIAISON(®) CMV IgG, IgM and IgG Avidity II assays. J Clin Virol. 2015;72:42-45.
17. Lagrou K, Bodeus M, Van Ranst M, et al. Evaluation of the new architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays. J Clin Microbiol. 2009;47:1695-1699.
18. Seed CR, Piscitelli LM, Maine GT, et al. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion. 2009;49:134-145.
19. Weber B, Fall EM, Berger A, et al. Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens. J Clin Virol. 1999;14:173-181.
20. Preiksaitis JK, Sandhu J, Strautman M. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center. Transfusion. 2002;42:396-402.
21. Ritter M, Schmidt T, Dirks J, et al. Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies. Eur J Immunol. 2013;43: 1099-1108.
22. Schmidt T, Ritter M, Dirks J, et al. Cytomegalovirus-specific T-cell immunity to assign the infection status in individuals with passive immunity: a proof of principle. J Clin Virol. 2012;54:272-275.
23. Schmidt T, Schub D, Wolf M, et al. Comparative analysis of assays for detection of cell-mediated immunity toward cytomegalovirus and M. tuberculosis in samples from deceased organ donors. Am J Transplant. 2014;14:2159-2167.
24. Mayer BT, Matrajt L, Casper C, et al. Dynamics of persistent oral cytomegalovirus shedding during primary infection in ugandan infants. J Infect Dis. 2016;214:1735-1743.
25. Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with longterm reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010;90:1427-1431.
26. Humar A, Mazzulli T, Moussa G, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant. 2005;5:1065-1070.
27. Blanco-Lobo P, Bulnes-Ramos A, McConnell MJ, et al. Applying lessons learned from cytomegalovirus infection in transplant patients to vaccine design. Drug Discov Today. 2016;21:674-681.
28. Pillay D, Ali AA, Liu SF, et al. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation. 1993;56:103-108.
29. Caliendo AM, St George K, Allega J, et al. Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays. J Clin Microbiol. 2002;40:1581-1586.
30. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2000;355:2032-2036.
31. Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation. 1999;68:1305-1311.
32. Humar A, Kumar D, Boivin G, et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis. 2002;186:829-833.
33. LaoWC, Lee D, Burroughs AK, et al. Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation. J Med Virol. 1997;51:152-158.
34. Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis. 2003;187:1801-1808.
35. Rollag H, Sagedal S, Kristiansen KI, et al. Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients. Clin Microbiol Infect. 2002;8:431-434.
36. Hamprecht K, Steinmassl M, Einsele H, et al. Discordant detection of human cytomegalovirus DNA from peripheral blood mononuclear cells, granulocytes and plasma: correlation to viremia and HCMV infection. J Clin Virol. 1998;11:125-136.
37. Koidl C, Bozic M, Marth E, et al. Detection of CMV DNA: is EDTA whole blood superior to EDTA plasma? J VirolMethods. 2008;154:210-212.
38. Lisboa LF, Asberg A, Kumar D, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation. 2011;91:231-236.
39. Razonable RR, Brown RA, Wilson J, et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation. 2002;73: 968-973.
40. TangW, Elmore SH, Fan H, et al. Cytomegalovirus DNA measurement in blood and plasma using Roche LightCycler CMV quantification reagents. Diagn Mol Pathol. 2008;17:166-173.
41. Tong Y, Pang XL, Mabilangan C, et al. Determination of the biological form of human cytomegalovirus DNA in the plasma of solid-organ transplant recipients. J Infect Dis. 2017.
42. Fryer JF HA, Anderson R, Minor PD, and the collaborative study group. Collaborative study to evaluate the proposed 1st WHO International Standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. 2010; WHO ECBS Report 2010; WHO/BS/2010.2138. Available at www.who.int/biologicals/expert-committee/TRS-978-61st-report.pdf?ua=1.
43. Preiksaitis JK, Hayden RT, Tong Y, et al. Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin Infect Dis. 2016;63: 583-589.
44. Hayden RT, Sun Y, Tang L, et al. Progress in quantitative viral load testing: variability and impact of the WHO quantitative international standards. J Clin Microbiol. 2017;55:423-430.
45. Hayden RT, Yan X, Wick MT, et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol. 2012;50:337-345.
46. Jones S, Webb EM, Barry CP, et al. Commutability of cytomegalovirus WHO international standard in different matrices. J Clin Microbiol. 2016;54:1512-1519.
47. Hayden RT, Gu Z, Sam SS, et al. Comparative evaluation of three commercial quantitative cytomegalovirus standards by use of digital and realtime PCR. J Clin Microbiol. 2015;53:1500-1505.
48. Tsai HP, Tsai YY, Lin IT, et al. Comparison of two commercial automated nucleic acid extraction and integrated quantitation real-time PCR platforms for the detection of cytomegalovirus in plasma. PLoS One. 2016; 11:e0160493.
49. Hayden RT, Preiksaitis J, Tong Y, et al. Commutability of the first World Health Organization international standard for human cytomegalovirus. J Clin Microbiol. 2015;53:3325-3333.
50. Hirsch HH, Lautenschlager I, Pinsky BA, et al. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis. 2013;56:367-373.
51. Caliendo AM, Schuurman R, Yen-Lieberman B, et al. Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma. J Clin Microbiol. 2001;39:1334-1338.
52. Lilleri D, Lazzarotto T, Ghisetti V, et al. Multicenter quality control study for human cytomegalovirus DNAemia quantification. New Microbiol. 2009; 32:245-253.
53. Abbate I, Piralla A, Calvario A, et al. Nation-wide measure of variability in HCMV, EBV and BKV DNA quantification among centers involved in monitoring transplanted patients. J Clin Virol. 2016;82:76-83.
54. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7:2106-2113.
55. Dioverti MV, Lahr B, Razonable RR. Treatment of cytomegalovirus infection and disease pre-and post-quantitative nucleic acid test standardization: does use of a more sensitive assay lead to longer treatment duration? Clin Transplant. 2016;30:154-160.
56. Razonable RR, Asberg A, Rollag H, et al. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis. 2013;56:1546-1553.
57. Chemaly RF, Yen-Lieberman B, Castilla EA, et al. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. J Clin Microbiol. 2004;42:2168-2172.
58. Solans EP, Yong S, Husain AN, et al. Bronchioloalveolar lavage in the diagnosis of CMV pneumonitis in lung transplant recipients: an immunocytochemical study. Diagn Cytopathol. 1997;16:350-352.
59. Halme L, Lempinen M, Arola J, et al. High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients. Apmis. 2008;116: 99-106.
60. Eid AJ, Arthurs SK, Deziel PJ, et al. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2010;10:157-161.
61. Westall GP, Michaelides A, Williams TJ, et al. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis. 2004;190:1076-1083.
62. Durand CM, Marr KA, Arnold CA, et al. Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients. Clin Infect Dis. 2013;57: 1550-1559.
63. Fisher CE, Alexander J, Bhattacharya R, et al. Sensitivity of blood and tissue diagnostics for gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Transpl Infect Dis. 2016;18:372-380.
64. McCoy MH, Post K, Sen JD, et al. qPCR increases sensitivity to detect cytomegalovirus in formalin-fixed, paraffin-embedded tissue of gastrointestinal biopsies. Hum Pathol. 2014;45:48-53.
65. Mills AM, Guo FP, Copland AP, et al. A comparison of CMV detection in gastrointestinal mucosal biopsies using immunohistochemistry and PCR performed on formalin-fixed, paraffin-embedded tissue. Am J Surg Pathol. 2013;37:995-1000.
66. Kerschner H, Jaksch P, Zweytick B, et al. Detection of human cytomegalovirus in bronchoalveolar lavage fluid of lung transplant recipients reflects local virus replication and not contamination from the throat. J Clin Microbiol. 2010;48:4273-4274.
67. Buffone GJ, Frost A, Samo T, et al. The diagnosis of CMV pneumonitis in lung and heart/lung transplant patients by PCR comparedwith traditional laboratory criteria. Transplantation. 1993;56:342-347.
68. Storch GA, Ettinger NA, Ockner D, et al. Quantitative cultures of the cell fraction and supernatant of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus pneumonitis in lung transplant recipients. J InfectDis. 1993;168:1502-1506.
69. Bauer CC, Jaksch P, Aberle SW, et al. Relationship between cytomegalovirus DNA load in epithelial lining fluid and plasma of lung transplant recipients and analysis of coinfection with Epstein-Barr virus and human herpesvirus 6 in the lung compartment. J Clin Microbiol. 2007;45:324-328.
70. Gerna G, Lilleri D, Rognoni V, et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant. 2009;9:1142-1150.
71. Riise GC, Andersson R, BergströmT, et al. Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients. Chest. 2000;118:1653-1660.
72. Puchhammer-Stöckl E. Herpesviruses and the transplanted lung: looking at the air side. J Clin Virol. 2008;43:415-418.
73. Kaminski H, Fishman JA. The cell biology of cytomegalovirus: implications for transplantation. Am J Transplant. 2016;16:2254-2269.
74. Carbone J. The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV. Transplantation. 2016;100(Suppl 3):S11-S18.
75. Fernandez-Ruiz M, Corrales I, Arias M, et al. Association between individual and combined SNPs in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant recipients. Am J Transplant. 2015;15:1323-1335.
76. de Rooij BJ, van der Beek MT, van Hoek B, et al. Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation. J Hepatol. 2011;55:800-807.
77. Cervera C, Lozano F, Linares L, et al. Influence ofmannose-binding lectin gene polymorphisms on the invasiveness of cytomegalovirus disease after solid organ transplantation. Transplant Proc. 2009;41:2259-2261.
78. Kwakkel-van Erp JM, Paantjens AW, van Kessel DA, et al. Mannosebinding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survival in lung transplantation. Clin Exp Immunol. 2011;165:410-416.
79. Sarmiento E, JaramilloM, Calahorra L, et al. Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: a multicenter prospective study. J Heart Lung Transplant. 2017;36:529-539.
80. Egli A, Levin A, Santer DM, et al. Immunomodulatory function of interleukin 28B during primary infection with cytomegalovirus. J Infect Dis. 2014; 210:717-727.
81. Lisboa LF, Egli A, Fairbanks J, et al. CCL8 and the immune control of cytomegalovirus in organ transplant recipients. Am J Transplant. 2015;15: 1882-1892.
82. Fernández-Ruiz M, Silva JT, López-Medrano F, et al. Post-transplant monitoring of NK cell counts as a simple approach to predict the occurrence of opportunistic infection in liver transplant recipients. Transpl Infect Dis. 2016;18:552-565.
83. Sarmiento E, del Pozo N, Gallego A, et al. Decreased levels of serum complement C3 and natural killer cells add to the predictive value of total immunoglobulin G for severe infection in heart transplant recipients. Transpl Infect Dis. 2012;14:526-539.
84. de Rham C, Hadaya K, Bandelier C, et al. Expression of killer cell immunoglobulin-like receptors (KIRs) by natural killer cells during acute CMV infection after kidney transplantation. Transpl Immunol. 2014;31: 157-164.
85. Gonzalez A, Schmitter K, Hirsch HH, et al. KIR-associated protection fromCMV replication requires pre-existing immunity: a prospective study in solid organ transplant recipients. Genes Immun. 2014;15:495-499.
86. van Duin D, Avery RK, Hemachandra S, et al. KIR and HLA interactions are associated with control of primary CMV infection in solid organ transplant recipients. Am J Transplant. 2014;14:156-162.
87. Ravens S, Schultze-Florey C, Raha S, et al. Human γδ Tcells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. Nat Immunol. 2017;18:393-401.
88. Knight A, Madrigal AJ, Grace S, et al. The role of Vδ2-negative γδ Tcells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood. 2010;116:2164-2172.
89. Kaminski H, Garrigue I, Couzi L, et al. Surveillance of γδ T cells predicts cytomegalovirus infection resolution in kidney transplants. J Am Soc Nephrol. 2016;27:637-645.
90. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. ClinMicrobiol Rev. 2009;22:76-98. Table of Contents.
91. Lilleri D, Kabanova A, Lanzavecchia A, et al. Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol. 2012;32:1324-1331.
92. Fouts AE, Chan P, Stephan JP, et al. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anticytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol. 2012;86:7444-7447.
93. Genini E, Percivalle E, Sarasini A, et al. Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol. 2011;52:113-118.
94. Doron S, Ruthazer R, Werner BG, et al. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation. 2006;81:697-703.
95. Ohsumi A, Chen F, Yamada T, et al. Effect of hypogammaglobulinemia after lung transplantation: a single-institution study. Eur J Cardiothorac Surg. 2014;45:e61-e67.
96. Mozer-Glassberg Y, Shamir R, Steinberg R, et al. Hypogammaglobulinemia in the early period after liver transplantation in children. Clin Transplant. 2013;27:E289-E294.
97. Fernandez-Ruiz M, Lopez-Medrano F, Varela-Pena P, et al. Monitoring of immunoglobulin levels identifies kidney transplant recipients at high risk of infection. Am J Transplant. 2012;12:2763-2773.
98. Sarmiento E, Navarro J, Fernandez-Yanez J, et al. Evaluation of an immunological score to assess the risk of severe infection in heart recipients. Transpl Infect Dis. 2014;16:802-812.
99. Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation. 2001;71:242-246.
100. Sarmiento E, Fernàndez-Yáñez J, Muñoz P, et al. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease. Int Immunopharmacol. 2005;5:97-101.
101. Yamani MH, Avery R, Mawhorter SD, et al. The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study. J Heart Lung Transplant. 2005;24: 1766-1769.
102. Yamani MH, Avery R, Mawhorter S, et al. Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes. Transpl Infect Dis. 2001;3 Suppl 2:40-43.
103. Sarmiento E, Diez P, Arraya M, et al. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial. Transpl Infect Dis. 2016;18:832-843.
104. Carbone J, Sarmiento E, Del Pozo N, et al. Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections. Clin Transplant. 2012;26:E277-E283.
105. Carbone J, Sarmiento E, Palomo J, et al. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections. Transplant Proc. 2007;39: 2385-2388.
106. Augusto JF, Garnier AS, Demiselle J, et al. Hypogammaglobulinemia and risk of severe infection in kidney transplant recipients. Transpl Infect Dis. 2016;18:741-751.
107. Nierenberg NE, Poutsiaka DD, Chow JK, et al. Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation. Liver Transpl. 2014;20:1497-1507.
108. Natori Y, Humar A, Husain S, et al. Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients. Transplantation. 2017;101:1449-1454.
109. Sood S, Testro AG. Immune monitoring post liver transplant. World J Transplant. 2014;4:30-39.
110. Carbone J, Lanio N, Gallego A, et al. Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients. J Clin Immunol. 2012;32:809-819.
111. Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirusspecific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis. 2012;55:1678-1689.
112. Sester M, Leboeuf C, Schmidt T, et al. The "ABC" of virus-specific T cell immunity in solid organ transplantation. Am J Transplant. 2016;16: 1697-1706.
113. Camargo JF, Resende MR, Zamel R, et al. Potential role of CC chemokine receptor 6 in prediction of late-onset cytomegalovirus infection following solid organ transplant. Clin Transplant. 2015;29:492-498.
114. Walker S, Fazou C, Crough T, et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERONCMV. Transpl Infect Dis. 2007;9:165-170.
115. Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant. 2008;8: 1749-1754.
116. Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirusspecific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56:817-824.
117. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant. 2009;9:1214-1222.
118. Cantisαn S, Lara R, MontejoM, et al. Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant. 2013;13:738-745.
119. Weseslindtner L, Kerschner H, Steinacher D, et al. Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ Tcell responses in lung transplant recipients. Am J Transplant. 2012;12:2172-2180.
120. Lisboa LF, Kumar D, Wilson LE, et al. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012;93:195-200.
121. Bestard O, Lucia M, Crespo E, et al. Pretransplant immediately early-1-specific Tcell responses provide protection forCMV infection after kidney transplantation. Am J Transplant. 2013;13:1793-1805.
122. Mattes FM, Vargas A, Kopycinski J, et al. Functional impairment of cytomegalovirus specific CD8 Tcells predicts high-level replication after renal transplantation. Am J Transplant. 2008;8:990-999.
123. Abate D, Fiscon M, Saldan A, et al. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection. J Clin Microbiol. 2012;50:1974-1980.
124. Abate D, Saldan A, FisconM, et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis. 2010;202:585-594.
125. Costa C, Astegiano S, Terlizzi ME, et al. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients. Transplant Proc. 2011;43:1159-1161.
126. Schachtner T, Stein M, Reinke P. CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor. Transplantation. 2017;101:e315-e325.
127. Lucia M, Crespo E, Melilli E, et al. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMVsensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis. 2014;59:1537-1545.
128. Shabir S, Kaul B, Pachnio A, et al. Impaired direct priming of CD8 Tcells by donor-derived cytomegalovirus following kidney transplantation. J Am Soc Nephrol. 2013;24:1698-1708.
129. Barabas S, Spindler T, Kiener R, et al. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring ofCMV protein-reactive effector cells of cell-mediated immunity. BMC Immunol. 2017;18:14.
130. Banas B, Böger CA, Lückhoff G, et al. Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunol. 2017;18:15.
131. Sester M, Sester U, Gartner B, et al. Levels of virus-specific CD4 T cells correlatewith cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation. 2001;71:1287-1294.
132. Gerna G, Lilleri D, Fornara C, et al. Monitoring of human cytomegalovirusspecific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant. 2006;6:2356-2364.
133. Gerna G, Lilleri D, Chiesa A, et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant. 2011;11:2463-2471.
134. Sester U, Gartner BC, Wilkens H, et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant. 2005;5:1483-1489.
135. Radha R, Jordan S, Puliyanda D, et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant. 2005;5:110-117.
136. Snyder LD, Chan C, Kwon D, et al. Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation. Am J Respir Crit CareMed. 2016;193:78-85.
137. Snyder LD, Medinas R, Chan C, et al. Polyfunctional cytomegalovirusspecific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am J Transplant. 2011;11:553-560.
138. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med. 2008;6:29.
139. Sester U, Presser D, Dirks J, et al. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant. 2008;8:1486-1497.
140. Nebbia G, Mattes FM, Smith C, et al. Polyfunctional cytomegalovirusspecific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant. 2008;8:2590-2599.
141. La Rosa C, Krishnan A, Longmate J, et al. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis. 2008;197:25-33.
142. Sund F, Lidehall AK, Claesson K, et al. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin Transplant. 2010;24:401-409.
143. Kumar D, Mian M, Singer L, et al. An interventional study using cellmediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant. 2017;17:2468-2473.
144. Brestrich G, Zwinger S, Fischer A, et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant. 2009;9:1679-1684.
145. Pierucci P, Malouf M, Glanville AR, et al. Novel autologous T-cell therapy for drug-resistant cytomegalovirus disease after lung transplantation. J Heart Lung Transplant. 2016;35:685-687.
146. Macesic N, Langsford D, Nicholls K, et al. Adoptive Tcell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient. Am J Transplant. 2015;15:827-832.
147. Gupta MP, Coombs P, Prockop SE, et al. Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion. Ophthalmic Surg Lasers Imaging Retina. 2015;46:80-82.
148. Holmes-Liew CL, Holmes M, Beagley L, et al. Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation. Clin Transl Immunology. 2015;4:e35.
149. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific Tcells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121:5113-5123.
150. Blyth E, Clancy L, Simms R, et al. Donor-derived CMV-specific Tcells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013;121:3745-3758.
151. Lugthart G, Albon SJ, Ricciardelli I, et al. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy. J Immunother. 2012;35:42-53.
152. Gerdemann U, Katari UL, Papadopoulou A, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed Tcells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013;21:2113-2121.
153. McVoyMA. Cytomegalovirus vaccines. Clin Infect Dis. 2013;57(Suppl 4): S196-S199.
154. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med. 1991;114:525-531.
155. Pass RF, Duliege AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoproteinB and a new adjuvant. J Infect Dis. 1999;180:970-975.
156. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl JMed. 2009;360:1191-1199.
157. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377:1256-1263.
158. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12:290-299.
159. Vincenti F, Budde K, Merville P, et al. Efficacy and Safety of ASP0113 versus Placebo in CMV-Seronegative Kidney Transplant Patients Receiving an Organ from a CMV-Seropositive Donor. Chicago, USA: Paper presented at: American Transplant Congress; 2017.
160. Nakamura R, La Rosa C, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016;3:e87-e98.
161. Reap EA, Morris J, Dryga SA, et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine. 2007;25:7441-7449.
162. Bernstein DI, Schleiss MR, Berencsi K, et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis. 2002;185:686-690.
163. Berencsi K, Gyulai Z, Gonczol E, et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis. 2001;183:1171-1179.
164. Zhong J, Rist M, Cooper L, et al. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PLoS One. 2008;3:e3256.
165. Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis. 2000;2:112-117.
166. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-620.
167. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl JMed. 1999;340:1462-1470.
168. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis. 2001;184:1461-1464.
169. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10:1228-1237.
170. Pang XL, Fox JD, Fenton JM, et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant. 2009;9:258-268.
171. Couzi L, Helou S, Bachelet T, et al. High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant. 2012;12:202-209.
172. Atabani SF, Smith C, Atkinson C, et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant. 2012;12:2457-2464.
173. Sun HY, Cacciarelli TV, Wagener MM, et al. Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients. Transpl Immunol. 2010;23:166-169.
174. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006;6:2134-2143.
175. Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8:69-77.
176. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8:975-983.
177. Witzke O, Hauser IA, Bartels M, et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation. 2012;93:61-68.
178. Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9:1205-1213.
179. Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother. 2013;45:260-271.
180. Reischig T, Nemcová J, Vanecek T, et al. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. Antivir Ther. 2010;15:23-30.
181. SpinnerML, Saab G, Casabar E, et al. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation. 2010;90:412-418.
182. Reischig T, Hribova P, Jindra P, et al. Long-term outcomes of preemptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2012;23:1588-1597.
183. Owers DS, Webster AC, Strippoli GF, et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013:CD005133.
184. Florescu DF, Qiu F, Schmidt CM, et al. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis. 2014;58:785-803.
185. Mumtaz K, Faisal N, Husain S, et al. Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2015;15:472-481.
186. Manuel O, Kralidis G, Mueller NJ, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2013;13:2402-2410.
187. Reischig T, Kacer M, Hruba P, et al. The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation. Antivir Ther. 2017.
188. Paraskeva M, Bailey M, Levvey BJ, et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant. 2011;11:2190-2196.
189. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med. 2010;181:1391-1396.
190. Zuk DM, Humar A, Weinkauf JG, et al. An international survey of cytomegalovirusmanagement practices in lung transplantation. Transplantation. 2010;90:672-676.
191. Lisboa LF, Preiksaitis JK, Humar A, et al. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation. 2011;92:1063-1068.
192. Montejo M, Montejo E, Gastaca M, et al. Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R-) liver transplant recipients: a single-center experience. Transplant Proc. 2009;41:2189-2191.
193. Boillat Blanco N, Pascual M, Venetz JP, et al. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation. 2011;91:251-255.
194. van der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation. 2010;89:320-326.
195. Martin-Gandul C, Perez-Romero P, Blanco-Lobo P, et al. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy. Transpl Int. 2014;27:1060-1068.
196. Griffiths PD, Rothwell E, Raza M, et al. Randomized controlled trials to define viral load thresholds for cytomegalovirus pre-emptive therapy. PLoS One. 2016;11:e0163722.
197. BoarettiM, Sorrentino A, Zantedeschi C, et al. Quantification of cytomegalovirus DNA by a fully automated real-time PCR for early diagnosis and monitoring of active viral infection in solid organ transplant recipients. J Clin Virol. 2013;56:124-128.
198. Martín-Gandul C, Pérez-Romero P, Sánchez M, et al. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol. 2013;56:13-18.
199. Vinuesa V, Gimenez E, Solano C, et al. Would kinetic analyses of plasma cytomegalovirus DNA load help to reach consensus criteria for triggering the initiation of preemptive antiviral therapy in transplant recipients? Clin Infect Dis. 2016;63:1533-1535.
200. Solano C, Gimenez E, Pinana JL, et al. Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood. BoneMarrow Transplant. 2016;51:718-721.
201. Gimenez E, Munoz-Cobo B, Solano C, et al. Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value? J Clin Microbiol. 2014;52:654-656.
202. Emery VC, Hassan-Walker AF, Burroughs AK, et al. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and-experienced immunocompromised hosts. J Infect Dis. 2002;185:1723-1728.
203. Schoeppler KE, Lyu DM, Grazia TJ, et al. Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis? Am J Transplant. 2013;13:376-382.
204. Hashim F, Gregg JA, Dharnidharka VR. Efficacy of extended valganciclovir prophylaxis in preventing cytomegalovirus infection in pediatric kidney transplantation. Open Urol Nephrol J. 2014;7(Suppl 2 M7):152-157.
205. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152:761-769.
206. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant. 2004;4:1635-1642.
207. Jaksch P, Zweytick B, Kerschner H, et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3-vs 12-month valganciclovir therapy. J Heart Lung Transplant. 2009;28:670-675.
208. Beam E, Lesnick T, Kremers W, et al. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis. Clin Transplant. 2016;30:270-278.
209. Wiita AP, Roubinian N, Khan Y, et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis. 2012;14:248-258.
210. Hodson EM, Ladhani M, Webster AC, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013:CD003774.
211. Reischig T, Jindra P, Mares J, et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation. 2005;79:317-324.
212. Pavlopoulou ID, Syriopoulou VP, Chelioti H, et al. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clin Microbiol Infect. 2005;11: 736-743.
213. Reischig T, KacerM, Jindra P, et al. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Clin J Am Soc Nephrol. 2015;10:294-304.
214. Reischig T, Prucha M, Sedlackova L, et al. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients. Antivir Ther. 2011;16:1227-1235.
215. Kacer M, Kielberger L, Bouda M, et al. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective. Transpl Infect Dis. 2015;17:334-341.
216. Lischka P, Michel D, Zimmermann H. Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis. 2016;213:23-30.
217. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370:1781-1789.
218. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017.
219. Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012;12:3021-3030.
220. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369:1227-1236.
221. AABB, Clinical Transfusion Medicine Committee, Heddle NM, Boeckh M, Grossman B, et al. AABB Committee Report: reducing transfusiontransmitted cytomegalovirus infections. Transfusion. 2016;56(6 Pt 2): 1581-1587.
222. Sullivan T, Brodginski A, Patel G, et al. The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients. Transplantation. 2015;99:855-859.
223. Helantera I, Lautenschlager I, Koskinen P. The risk of cytomegalovirus recurrence after kidney transplantation. Transpl Int. 2011;24:1170-1178.
224. Nafar M, Roshan A, Pour-Reza-Gholi F, et al. Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients. Iran J Kidney Dis. 2014;8:231-235.
225. Moreno A, Cervera C, Fortún J, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl. 2012;18:70-81.
226. Lee YM, Kim YH, Han DJ, et al. Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients. Transpl Infect Dis. 2014;16:397-402.
227. Santos CA, Brennan DC, Fraser VJ, et al. Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation. Transplantation. 2014;98:187-194.
228. Ong DS, Klein Klouwenberg PM, Verduyn Lunel FM, et al. Cytomegalovirus seroprevalence as a risk factor for poor outcome in acute respiratory distress syndrome. Crit Care Med. 2015;43:394-400.
229. Walton AH, Muenzer JT, Rasche D, et al. Reactivation of multiple viruses in patients with sepsis. PLoS One. 2014;9:e98819.
230. Ong DS, Spitoni C, Klein Klouwenberg PM, et al. Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome. Intensive Care Med. 2016;42:333-341.
231. Limaye AP, Stapleton RD, Peng L, et al. Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial. JAMA. 2017;318:731-740.
232. Cowley NJ, Owen A, Shiels SC, et al. Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial. JAMA Intern Med. 2017; 177:774-783.
233. Le Page AK, Jager MM, Kotton CN, et al. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation. 2013;95:1455-1460.
234. Chamberlain CE, Penzak SR, Alfaro RM, et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant. 2008;8:1297-1302.
235. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44:2811-2815.
236. Stevens DR, Sawinski D, Blumberg E, et al. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl Infect Dis. 2015;17:163-173.
237. Gabardi S, Asipenko N, Fleming J, et al. Evaluation of low-versus highdose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Transplantation. 2015;99:1499-1505.
238. Heldenbrand S, Li C, Cross RP, et al. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients. Transpl Infect Dis. 2016;18:904-912.
239. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renaltransplant recipients. N Engl JMed. 1987;317:1049-1054.
240. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1993;119:984-991.
241. Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation. 2001; 72:1647-1652.
242. Florescu DF, Abu-Elmagd K, Mercer DF, et al. An international survey of cytomegalovirus prevention and treatment practices in intestinal transplantation. Transplantation. 2014;97:78-82.
243. Ruttmann E, Geltner C, Bucher B, et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation. 2006;81:1415-1420.
244. Rubin RH, Lynch P, Pasternack MS, et al. Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob Agents Chemother. 1989;33: 1975-1979.
245. Miescher SM, Huber TM, Kühne M, et al. In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins. Vox Sang. 2015;109:71-78.
246. Germer M, Herbener P, Schüttrumpf J. Functional properties of human cytomegalovirus hyperimmunoglobulin and standard immunoglobulin preparations. Ann Transplant. 2016;21:558-564.
247. Ishida JH, Patel A, Mehta AK, et al. Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients. Antimicrob Agents Chemother. 2017;61.
248. Dole K, Segal FP, Feire A, et al. A first-in-human study to assess the safety and pharmacokinetics of monoclonal antibodies against human cytomegalovirus in healthy volunteers. Antimicrob Agents Chemother. 2016;60:2881-2887.
249. Andrassy J, Hoffmann VS, Rentsch M, et al. Is cytomegalovirus prophylaxis dispensable in patients receiving anmTORinhibitor-based immunosuppression? A systematic review and meta-analysis. Transplantation. 2012;94:1208-1217.
250. Su L, Tam N, Deng R, et al. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis. Int Urol Nephrol. 2014;46:2035-2044.
251. Radtke J, Dietze N, Spetzler VN, et al. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid. Transpl Infect Dis. 2016;18:79-88.
252. Cervera C, Cofan F, Hernandez C, et al. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis. Transpl Int. 2016;29:1216-1225.
253. Sheng L, Jun S, Jianfeng L, et al. The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation. Clin Transplant. 2015;29:555-559.
254. Kobashigawa J, Ross H, Bara C, et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis. 2013;15:150-162.
255. Díaz Molina B, Velasco Alonso E, Lambert Rodríguez JL, et al. Effect of early conversion to everolimus together with prophylaxis with valganciclovir in the prevention of cytomegalovirus infection in heart transplant recipients. Transplant Proc. 2015;47:130-131.
256. Durante-Mangoni E, Andini R, Pinto D, et al. Effect of the immunosuppressive regimen on the incidence of cytomegalovirus infection in 378 heart transplant recipients: a single centre, prospective cohort study. J Clin Virol. 2015;68:37-42.
257. Ghassemieh B, Ahya VN, Baz MA, et al. Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation. J Heart Lung Transplant. 2013;32:701-706.
258. Rittà M, Costa C, Solidoro P, et al. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection. Antiviral Res. 2015;113:19-26.
259. Strueber M, Warnecke G, Fuge J, et al. Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial. Am J Transplant. 2016;16:3171-3180.
260. Hocker B, Zencke S, Pape L, et al. Impact of everolimus and low-dose cyclosporin on cytomegalovirus replication and disease in pediatric renal transplantation. Am J Transplant. 2016;16:921-929.
261. Pascual J, Royuela A, Fernandez AM, et al. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis. 2016;18(6):819-831.
262. Tedesco-Silva H, Felipe C, Ferreira A, et al. Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant. 2015;15:2655-2664.
263. Product Monograph Valcyte® Hoffmann-La Roche Limited (USA). Patient Information and Instructions for Use. 2017; https://www.gene.com/download/pdf/valcyte-prescribing.pdf. Accessed December 17, 2017.
264. Product Monograph Valcyte® Hoffmann-La Roche Limited (Canada). 2017; https://www.gene.com/download/pdf/valcyte-prescribing.pdf.Accessed December 17, 2017.
265. Product Monograph Cytovene® Hoffmann-La Roche Limited/CYTOVENE®-IV (ganciclovir sodium for injection) 2017; https://www.gene.com/download/pdf/cytovene-prescribing.pdf. Accessed December 17, 2017.
266. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibodypositive renal transplant recipients. A randomized controlled trial. Ann Intern Med. 1995;123:18-26.
267. LeFevre PG, Jung CY, Chaney JE. Glucose transfer by red cell membrane phospholipids in H2O-CHCl-3-H2O three-layer systems. Arch Biochem Biophys. 1968;126:677-691.
268. Toyoda M, Shin BH, Ge S, et al. Impact of desensitization on antiviral immunity in HLA-sensitized kidney transplant recipients. J Immunol Res. 2017;2017:5672523.
269. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A. 2000;97:8039-8044.
270. McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;61:1153-1183.
271. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
272. Padulles A, ColomH, Bestard O, et al. Contribution of population pharmacokinetics to dose optimization of ganciclovir-valganciclovir in solid-organ transplant patients. Antimicrob Agents Chemother. 2016;60:1992-2002.
273. Asberg A, Jardine AG, Bignamini AA, et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant. 2010;10:1881-1888.
274. Asberg A, Humar A, Rollag H, et al. Lessons learned from a randomized study of oral valganciclovir versus parenteral ganciclovir treatment of cytomegalovirus disease in solid organ transplant recipients: the VICTOR trial. Clin Infect Dis. 2016;62:1154-1160.
275. Boivin G, Goyette N, Rollag H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther. 2009;14:697-704.
276. Gardiner BL, Chow JK, Price LL. Role of secondary prophylaxis with valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis. 2017;65:2000-2007.
277. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23:689-712.
278. Fisher CE, Knudsen JL, Lease ED, et al. Risk factors and outcomes of ganciclovir resistant cytomegalovirus infection in solid organ transplant recipients. Clin Infect Dis. 2017;65:57-63.
279. Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother. 2010;65:2628-2640.
280. Myhre HA, Haug Dorenberg D, Kristiansen KI, et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation. 2011;92:217-223.
281. Young PG, Rubin J, Angarone M, et al. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study. Transpl Infect Dis. 2016;18:390-395.
282. Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis. 2002;186(6):760-768.
283. Ambrose T, Sharkey LM, Louis-Auguste J, et al. Cytomegalovirus infection and rates of antiviral resistance following intestinal and multivisceral transplantation. Transplant Proc. 2016;48:492-496.
284. Timpone JG, Yimen M, Cox S, et al. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients. Transpl Infect Dis. 2016;18: 202-209.
285. Boivin G, Goyette N, FarhanM, et al. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol. 2012;53:208-213.
286. Jabs DA, Enger C, Forman M, et al. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother. 1998;42:2240-2244.
287. Schubert A, Ehlert K, Schuler-Luettmann S, et al. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. BMC Infect Dis. 2013;13:330.
288. Strasfeld L, Lee I, Villano S, et al. Virologic characterization ofmulti-drugresistant cytomegalovirus infection in two transplant recipients treated with maribavir. J Infect Dis. 2010;202:104-108.
289. Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22:162-170.
290. Bonatti H, Sifri CD, Larcher C, et al. Use of cidofovir for cytomegalovirus disease refractory to ganciclovir in solid organ recipients. Surg Infect (Larchmt). 2017;18:128-136.
291. Avery RK, Arav-Boger R, Marr KA, et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection. Transplantation. 2016;100:e74-e80.
292. Landry ML, Stanat S, Biron K, et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother. 2000;44:688-692.
293. Sahoo MK, Lefterova MI, Yamamoto F, et al. Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol. 2013;51:3700-3710.
294. Chou S, Boivin G, Ives J, et al. Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. J Infect Dis. 2014;209:1209-1216.
295. Chou S, Ercolani RJ, Sahoo MK, et al. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob Agents Chemother. 2014;58:4697-4702.
296. Garrigue I, Moulinas R, Recordon-Pinson P, et al. Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients. J Clin Virol. 2016;80:74-81.
297. Houldcroft CJ, Bryant JM, Depledge DP, et al. Detection of lowfrequency multi-drug resistance and novel putativemaribavir resistance in immunocompromised pediatric patients with cytomegalovirus. Front Microbiol. 2016;7:1317.
298. Hamprecht K, Eckle T, Prix L, et al. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis. 2003;187:139-143.
299. LiuW, Kuppermann BD, Martin DF, et al. Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis. J InfectDis. 1998;177:1176-1181.
300. Campos AB, Ribeiro J, Boutolleau D, et al. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art. Rev Med Virol. 2016;26:161-182.
301. Chevillotte M, von Einem J, Meier BM, et al. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res. 2010;85:318-327.
302. Komatsu TE, Pikis A, Naeger LK, et al. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways. Antiviral Res. 2014;101:12-25.
303. Chou S, Ercolani RJ, Vanarsdall AL. Differentiated levels of ganciclovir resistance conferred by mutations at codons 591 to 603 of the cytomegalovirus UL97 kinase gene. J Clin Microbiol. 2017;55:2098-2104.
304. Kleiboeker S, Nutt J, Schindel B, et al. Cytomegalovirus antiviral resistance: characterization of results from clinical specimens. Transpl Infect Dis. 2014;16:561-567.
305. Chou S, Marousek GI, Van Wechel LC, et al. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother. 2007;51:4160-4162.
306. Fischer L, Imrich E, Sampaio KL, et al. Identification of resistanceassociated HCMV UL97-and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. Antiviral Res. 2016;131:1-8.
307. Perrottet N, Decosterd LA, Meylan P, et al. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet. 2009;48:399-418.
308. Gagermeier JP, Rusinak JD, Lurain NS, et al. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. Transpl Infect Dis. 2014;16:941-950.
309. Smith JP, Weller S, Johnson B, et al. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother. 2010;54:1146-1151.
310. BedinoG, Esposito P, Bosio F, et al. The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation. Int Urol Nephrol. 2013;45:1809-1813.
311. Gracia-Ahufinger I, Gutierrez-Aroca J, Cordero E, et al. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducingmutations. Transplantation. 2013;95:1015-1020.
312. Minces LR, Nguyen MH, Mitsani D, et al. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother. 2014;58:128-135.
313. Bonatti H, Sifri CD, Larcher C, et al. Use of cidofovir for cytomegalovirus disease refractory to ganciclovir in solid organ recipients. Surg Infect (Larchmt). 2016.
314. Patel SJ, Kuten SA, Knight RJ, et al. Resolution of mild ganciclovirresistant cytomegalovirus disease with reduced-dose cidofovir and CMV-hyperimmune globulin. J Transplant. 2014;2014:342319.
315. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11:1079-1084.
316. Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broadspectrum Tcells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6:242ra283.
317. Chou S, Van Wechel LC, Marousek GI. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob Agents Chemother. 2006;50:2557-2559.
318. Drouot E, Piret J, Boivin G. Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus. Antivir Ther. 2016;21:535-539.
319. Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation. 2012;93:1075-1085.
320. Ozaki KS, Camara NO, Nogueira E, et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin Transplant. 2007;21:675-680.
321. Sabe N, Gonzalez-Costello J, Rama I, et al. Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors. Transpl Int. 2012;25:e78-e82.
322. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 2010; 90:419-426.
323. Chon WJ, Kadambi PV, Xu C, et al. Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago. Case Rep Nephrol Dial. 2015;5:96-105.
324. Morita S, Shinoda K, Tamaki S, et al. Successful low-dose leflunomide treatment for ganciclovir-resistant cytomegalovirus infection with highlevel antigenemia in a kidney transplant: a case report and literature review. J Clin Virol. 2016;82:133-138.
325. Verkaik NJ, Hoek RA, van Bergeijk H, et al. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature. Transpl Infect Dis. 2013;15:E243-E249.
326. Germi R, Mariette C, Alain S, et al. Success and failure of artesunate treatment in five transplant recipients with disease caused by drugresistant cytomegalovirus. Antiviral Res. 2014;101:57-61.
327. Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis. 2008;46: 1455-1457.
328. Marty FM, Winston DJ, Chemaly RF, et al. Brincidofovir for prevention of cytomegalovirus after allogeneic hematopoietic cell transplantation in CMV-seropositive patients. BMT Tandem Meetings, Honolulu HI. 2016.
329. El-Haddad D, El Chaer F, Vanichanan J, et al. Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: a single-center experience. Antiviral Res. 2016; 134:58-62.
330. Chou S, Ercolani RJ, Lanier ER. Novel cytomegalovirus UL54 DNA polymerase gene mutations selected in vitro that confer brincidofovir resistance. Antimicrob Agents Chemother. 2016;60:3845-3848.
331. Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263 W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002;46:2365-2372.
332. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stemcell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11:284-292.
333. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12:489-496.
334. Alain S, Gomes M, Moulinas R, et al. Bridging the gap? Benefits and emergence of resistance using maribavir as rescue therapy in European transplant recipients. 15th International CMV/Betaherpesvirus Workshop, Brisbane, Australia. 2015: Abstract O59.
335. Papanicolaou G, Silveira FP, Langston A, et al. Maribavir for treatment of cytomegalovirus infections resistant or refractory to ganciclovir or foscarnet in hematopoietic stem cell transplant or solid organ transplant recipients: a randomized, dose-ranging double-blind, Phase 2 study. ID Week, New Orleans, LA. 2016: Abstract 78.
336. Chou S, Hakki M, Villano S. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. Antiviral Res. 2012;95:88-92.
337. Chou S, Ercolani RJ, Marousek G, et al. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. Antimicrob Agents Chemother. 2013;57:3375-3379.
338. Chou S. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother. 2015;59:6588-6593.
339. Goldner T, Hempel C, Ruebsamen-Schaeff H, et al. Geno-and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58:610-613.
340. Product Monograph PREVYMIS™ (letermovir) Merck (USA). PRESCRIBING INFORMATION 2017. https://www.accessdata.fda.gov/drugsatfda-docs/label/2017/209939Orig1s000,209940Orig1s000lbl. pdf. Accessed December 28, 2017.
341. Razonable RR, Humar A. AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):93-106.
342. Bowman JS, Green M, Scantlebury VP, et al. OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant. 1991;5:294-300.
343. Iragorri S, Pillay D, ScrineM, et al. Prospective cytomegalovirus surveillance in paediatric renal transplant patients. Pediatr Nephrol. 1993;7:55-60.
344. Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant. 2006;6:1906-1912.
345. Gerna G, Lilleri D, Callegaro A, et al. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. Transplantation. 2008;86:163-166.
346. Nicastro E, Giovannozzi S, Stroppa P, et al. Effectiveness of preemptive therapy for cytomegalovirus disease in pediatric liver transplantation. Transplantation. 2017;101:804-810.
347. Madan RP, Campbell AL, Shust GF, et al. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients. Transplantation. 2009;87:1318-1324.
348. Saitoh A, Sakamoto S, Fukuda A, et al. A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation. Transplantation. 2011;92:930-935.
349. Furuichi M, Fujiwara T, Fukuda A, et al. Fulminant hepatic failure as a risk factor for cytomegalovirus infection in children receiving preemptive therapy after living donor liver transplantation. Transplantation. 2016;100: 2404-2409.
350. Verma A, Palaniswamy K, CremoniniG, et al. Late cytomegalovirus infection in children: high incidence of allograft rejection and hepatitis in donor negative and seropositive liver transplant recipients. Pediatr Transplant. 2017;21.
351. Bueno J, Green M, Kocoshis S, et al. Cytomegalovirus infection after intestinal transplantation in children. Clin Infect Dis. 1997;25:1078-1083.
352. Nayyar N, Mazariegos G, Ranganathan S, et al. Pediatric small bowel transplantation. Semin Pediatr Surg. 2010;19:68-77.
353. Kranz B, Vester U, Wingen AM, et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant. 2008;12:474-478.
354. Smith JM, Corey L, Bittner R, et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol. 2010;21:1579-1586.
355. Höcker B, Zencke S, Krupka K, et al. Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (val-) ganciclovir. Transplantation. 2016;100:862-870.
356. Lin A, Worley S, Brubaker J, et al. Assessment of cytomegalovirus hybrid preventative strategy in pediatric heart transplant patients. J Pediatric Infect Dis Soc. 2012;1:278-283.
357. Mahle WT, Fourshee MT, Naftel DM, et al. Does cytomegalovirus serology impact outcome after pediatric heart transplantation? J Heart Lung Transplant. 2009;28:1299-1305.
358. Danziger-Isakov LA, Worley S, Michaels MG, et al. The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation. Transplantation. 2009;87:1541-1548.
359. Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis. 1999;1(Suppl 1):8-12.
360. Yamada A, Tashiro A, Hiraiwa T, et al. Long-term outcome of pediatric renal transplantation: a single center study in Japan. Pediatr Transplant. 2014;18:453-462.
361. Danziger-Isakov LA, Worley S, Arrigain S, et al. Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation. J Heart Lung Transplant. 2008;27:655-661.
362. Liu M, Worley S, Arrigain S, et al. Respiratory viral infections within one year after pediatric lung transplant. Transpl Infect Dis. 2009;11:304-312.
363. Snydman DR, Kistler KD, Ulsh P, et al. Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients. Transplantation. 2010;90:1432-1438.
364. Hussain T, Burch M, Fenton MJ, et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation. 2007;115:1798-1805.
365. Indolfi G, Heaton N, Smith M, et al. Effect of early EBV and/or CMV viremia on graft function and acute cellular rejection in pediatric liver transplantation. Clin Transplant. 2012;26:E55-E61.
366. Camacho-Gonzalez AF, Gutman J, Hymes LC, et al. 24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience. Transplantation. 2011;91:245-250.
367. Varela-Fascinetto G, BenchimolC, Reyes-Acevedo R, et al. Tolerability of up to 200 days of prophylaxis with valganciclovir oral solution and/or filmcoated tablets in pediatric kidney transplant recipients at risk of cytomegalovirus disease. Pediatr Transplant. 2017;21.
368. Patel M, Stefanidou M, Long CB, et al. Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients. Pediatr Transplant. 2012;16:18-28.
369. Lidehall AK, Engman ML, Sund F, et al. Cytomegalovirus-specific CD4 and CD8 T cell responses in infants and children. Scand J Immunol. 2013;77:135-143.
370. Krampe K, Briem-Richter A, Fischer L, et al. The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen. Pediatr Transplant. 2010;14:67-71.
371. Florescu DF, Langnas AN, GrantW, et al. Incidence, risk factors, and outcomes associated with cytomegalovirus disease in small bowel transplant recipients. Pediatr Transplant. 2012;16:294-301.
372. Green M, Kaufmann M, Wilson J, et al. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis. 1997;25:1344-1349.
373. Neyts J, Jähne G, Andrei G, et al. In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine. Antimicrob Agents Chemother. 1995;39:56-60.
374. Spivey JF, Singleton D, Sweet S, et al. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Pediatr Transplant. 2007; 11:312-318.
375. Pescovitz MD, Ettenger RB, Strife CF, et al. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis. 2010;12:195-203.
376. Vaudry W, Ettenger R, Jara P, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant. 2009;9:636-643.
377. Bradley D, Moreira S, Subramoney V, et al. Pharmacokinetics and safety of valganciclovir in pediatric heart transplant recipients 4 months of age and younger. Pediatr Infect Dis J. 2016;35:1324-1328.
378. Asberg A, Bjerre A, Neely M. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. Pediatr Transplant. 2014;18: 103-111.
379. Villeneuve D, Brothers A, Harvey E, et al. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. Pediatr Transplant. 2013;17:80-85.
380. Launay E, Theoret Y, Litalien C, et al. Pharmacokinetic profile of valganciclovir in pediatric transplant recipients. Pediatr Infect Dis J. 2012;31:405-407.
381. Ranganathan K, Worley S, Michaels MG, et al. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation. J Heart Lung Transplant. 2009;28:1050-1056.
382. Renoult E, Clermont MJ, Phan V, et al. Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients. Pediatr Transplant. 2008;12:420-425.
383. Snydman DR, Kistler KD, Ulsh P, et al. The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database. Clin Transplant. 2011;25:E455-E462.
384. Nagai S, Mangus RS, Anderson E, et al. Cytomegalovirus infection after intestinal/multivisceral transplantation: a single-center experience with 210 cases. Transplantation. 2016;100:451-460.
385. Gilbert C, BoivinG. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother. 2005;49:873-883.
386. Kim YJ, Boeckh M, Cook L, et al. Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients. Transpl Infect Dis. 2012;14:611-617.
387. MartinM, Goyette N, Ives J, et al. Incidence and characterization of cytomegalovirus resistancemutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J Clin Virol. 2010;47: 321-324.
388. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in childrenwith CKD. J Am Soc Nephrol. 2009;20:629-637.